Table 2.

Impact of primary tumor and resection site on the success rate of the initial TIL outgrowth and TIL/fragment

CategoryAll samplesSamples with >40 × 106 TILPaMean TIL/fragment (×106)Pb
Mitotic figures0.510.02
 <5.04530 (67)c18.93
 >5.04526 (58)8.22
Ulceration0.560.34
 Yes5836 (62)11.43
 No5739 (68)15.11
Breslow0.770.14
 <1.0 mm3321 (64)18.06
 1.01–2.0 mm3521 (60)12.70
 2.01–4.0 mm4327 (63)10.60
 >4.0 mm2915 (52)6.89
TIL presence0.040.28
 Non-brisk8957 (64)13.5
 Absent300
 Brisk22 (100)31.2
Primary site0.100.52
 Skin172103 (60)12.70
 Unknown3123 (74)15.98
 Acral116 (55)13.96
 Mucosal76 (86)9.04
 Choroid51 (20)0.73
Skin0.300.09
 Torso6643 (65)10.01
 Lower limbs4220 (48)12.22
 Face/neck/scalp3823 (61)12.11
 Upper limbs2617 (65)21.20
Skin histology0.080.46
 Superficial spreading5234 (65)13.74
 Nodular3419 (56)11.56
 Unclassified1613 (81)19.49
 Lentigo maligna51 (20)1.27
 Desmoplastic22 (100)17.63
Mutation tested0.170.59
 B-RAF6243 (69)16.63
 N-RAS2110 (48)19.50
 WT/WT159 (60)12.58
 C-KIT33 (100)30.50
TIL biopsy site0.050.39
 Skin/subcutaneous8645 (52)10.22
 Lymph node7548 (64)14.85
 Viscera5641 (73)13.34
 More than 1 site54 (80)23.25
 Brain41 (25)11.08
  • aFisher's exact test was used. P values below 0.05 are in bold.

  • bWilcoxon rank-sum test or Kruskal–Wallis test was used.

  • cNumbers in parentheses indicate percentage successful TIL growers based on total number in that group shown in the All samples column.